Another GLP-1 Drug Access Model: Will a Co-Pay ...

By Rene Pretorius

May 26, 2025

High costs of GLP-1 receptor agonists like Wegovy and Zepbound—often exceeding $1,000 monthly—limit access for patients seeking effective obesity and diabetes treatments. These barriers fuel demand for innovativ...
Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists
MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alig...
EMA AI Tool Qualification: How the AIM-NASH Approval Sets a Roadmap for Medic...
A System Dynamics Approach to Lowering Drug Prices by 30–80% in the US
Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030
VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options
Revolutionizing Hepatitis C Treatment: The Transformative Role of Direct-Acti...
First At-Home HPV Testing Approval: FDA Clears Teal Wand
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel
South Africa NHI Bill Court Ruling Calls for Scrutiny